-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CLB-3000 in Hepatitis B
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CLB-3000 in Hepatitis B report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CLB-3000 in Hepatitis B Drug Details: CLB-3000 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6084 in Hepatitis B
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6084 in Hepatitis B report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6084 in Hepatitis B Drug Details: RG-6084 (RO-7191863) is under development...
-
Company Profile
Aligos Therapeutics Inc – Company Profile
Aligos Therapeutics, Inc (Aligos) is a clinical-stage biopharmaceutical company that develops products for the treatment of viral infections and liver diseases. The company product pipeline includes ALG-125755 and ALG-000184 for the treatment of chronic hepatitis B (CHB) and ALG-097558 for covid 19. Aligos also provide ALG-055009 for Nonalcoholic Steatohepatitis (NASH). Its partners include Merck, Luxna Biotech, KU Leuven, AM Chemicals and Emory University. It operates in the US, Belgium, China and Australia. Aligos is headquartered in South San Francisco, California,...
Add to Basket -
Product Insights
Net Present Value Model: RG-6084
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model RG-6084 Drug Details RG-6084 (RO-7191863) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RG-6084
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry RG-6084 Drug Details RG-6084 (RO-7191863) is under development for the treatment of chronic hepatitis...
-
Sector Analysis
Chronic Hepatitis B (CHB) – Epidemiology Forecast to 2029
Hepatitis B is a liver disease caused by the hepatitis B virus (HBV). Hepatitis B is transmitted from person to person through blood, semen, and other body fluids (CDC, 2020; Mayo Clinic, 2020). Hepatitis B is a vaccine-preventable disease, but there is no cure if you have the disease. Chronic hepatitis B (CHB) occurs when the immune system cannot fight the infection and it remains in the body for six months or longer. CHB can be a life-threatening disease, and...
-
Sector Analysis
Hepatitis B Virus Infection – Global Drug Forecast and Market Analysis to 2029
Chronic hepatitis B (CHB) is a serious liver disease caused by the failure of viral clearance following acute hepatitis B virus (HBV) infection. The global disease burden is high in the nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, Brazil, and China); it is especially high in China. For most patients, CHB is a lifelong disease that cannot be cured, with only a very small number of patients entering remission each year. Patients with CHB have a...